XML 87 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Taxes [Line Items]    
Deferred tax assets, valuation allowance $ 723,583,000 $ 753,388,000
Deferred tax asset,Increase (decrease) in valuation allowance (29,800,000)  
Gross deferred tax assets before allowance 726,404,000 756,060,000
Net deferred tax assets before allowance 723,583,000 753,388,000
Capitalization of R&D costs 42,400,000 42,300,000
Global intangible low-taxed income $ 59,627,000  
Net operating loss carryforward period 3 years  
Interest and penalties $ 0 0
Accrued for interest and penalties $ 0 0
Income tax examination description Generally, the tax years 2021 through 2023 remain open and subject to examination by the major taxing jurisdictions to which the Company is subject.  
U.S [Member]    
Income Taxes [Line Items]    
R&D costs amortization period 5 years  
Non - U.S [Member]    
Income Taxes [Line Items]    
R&D costs amortization period 15 years  
Federal [Member]    
Income Taxes [Line Items]    
Net operating loss carryforwards $ 422,500,000 494,100,000
Research and development tax credit carryforwards 107,800,000  
Net operating loss carryforward indefinitely $ 420,900,000  
Net operating loss carryforward expiration year 2025  
Research and development tax credit carryforward expiration year 2025  
State [Member]    
Income Taxes [Line Items]    
Net operating loss carryforwards $ 621,800,000 524,000,000
Research and development tax credit carryforwards $ 26,400,000  
Net operating loss carryforward expiration year 2025  
Research and development tax credit carryforward expiration year 2025  
Foreign [Member]    
Income Taxes [Line Items]    
Net operating loss carryforwards $ 1,515,700,000 $ 1,663,300,000
Net operating loss carryforward expiration year 2027